0RJT Stock Chart & Stats
€69.25
€2.55(3.82%)
At close: 4:00 PM EDT
€69.25
€2.55(3.82%)
Day’s Range― - ―
52-Week Range€30.20 - €94.90
Previous CloseN/A
Volume1.09K
Average Volume (3M)20.16K
Market Cap
€1.26B
Enterprise Value€1.61K
Total Cash (Recent Filing)€118.90M
Total Debt (Recent Filing)€354.70M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Oct 29, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding20,578,390
10 Day Avg. Volume18,448
30 Day Avg. Volume20,160
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.85
Price to Sales (P/S)0.45
P/FCF Ratio-23.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€91.29Price Target Upside31.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.37
Revenue Forecast (FY)€3.42B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And ScaleSustained top-line expansion over multiple years reflects successful market penetration and platform adoption across European markets. Scale improves bargaining power with suppliers, spreads fixed fulfillment costs, and supports higher lifetime value from cross‑sell categories, aiding durable margin improvement.
Improving Operating Profitability (positive EBITDA)A positive and rising EBITDA margin indicates the business is capturing operating leverage as revenue grows. This trend suggests structural cost efficiencies in fulfillment, marketing and platform operations that can translate to sustainable operating cash flow if the company continues scaling and reduces one-time costs.
Materially Reduced Leverage And Stable Equity BaseSignificantly lower reported debt and a stable equity base reduce refinancing and solvency risk, providing financial flexibility. This balance-sheet strength supports continued reinvestment in logistics and tech, and cushions the company while it pursues profitability and cross‑market expansion.
Bears Say
Persistent Net LossesDespite revenue and EBITDA progress, continued net losses mean the firm has not converted scale into consistent bottom-line profit. Ongoing losses can erode equity, require periodic financing, and limit strategic options if not closed into sustained net profitability over the medium term.
Weak And Volatile Cash GenerationMaterial negative free cash flow and a recent decline in operating cash flow increase funding risk. Volatile cash conversion suggests working-capital pressure or heavy reinvestment, which can force external financing, slow margin improvement, or constrain investments in logistics and customer acquisition.
Exposure To Regulatory And Reimbursement VariabilityThe Rx business depends on national reimbursement rules and e‑prescription integration; differing country frameworks create operational complexity and timing risk. Regulatory shifts or delayed e‑prescription adoption can materially impact addressable market and long‑term revenue mix.
0RJT FAQ
What was Redcare Pharmacy’s price range in the past 12 months?
Redcare Pharmacy lowest share price was €30.20 and its highest was €94.90 in the past 12 months.
What is Redcare Pharmacy’s market cap?
Redcare Pharmacy’s market cap is €1.26B.
When is Redcare Pharmacy’s upcoming earnings report date?
Redcare Pharmacy’s upcoming earnings report date is Oct 29, 2026 which is in 73 days.
How were Redcare Pharmacy’s earnings last quarter?
Redcare Pharmacy released its earnings results on Jul 29, 2026. The company reported €0.229 earnings per share for the quarter, beating the consensus estimate of -€0.27 by €0.499.
Is Redcare Pharmacy overvalued?
According to Wall Street analysts Redcare Pharmacy’s price is currently Undervalued.
Does Redcare Pharmacy pay dividends?
Redcare Pharmacy does not currently pay dividends.
What is Redcare Pharmacy’s EPS estimate?
Redcare Pharmacy’s EPS estimate is 0.07.
How many shares outstanding does Redcare Pharmacy have?
Redcare Pharmacy has 20,578,390 shares outstanding.
What happened to Redcare Pharmacy’s price movement after its last earnings report?
Redcare Pharmacy reported an EPS of €0.229 in its last earnings report, beating expectations of -€0.27. Following the earnings report the stock price went up 0.219%.
Which hedge fund is a major shareholder of Redcare Pharmacy?
Currently, no hedge funds are holding shares in GB:0RJT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Redcare Pharmacy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€91.29 (31.82% Upside)
€91.29 (31.82% Upside)
Insider Transactions
Sold Shares
Worth €168.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.04%
Trailing 12-Months
Company Description
Redcare Pharmacy
Redcare Pharmacy N.V. manages and runs a network of digital pharmacies across Germany, Austria, Switzerland, France, Belgium, Italy, and the Netherlands. The company offers a comprehensive selection of healthcare products, including prescription medications, over-the-counter drugs, pharmacy-related beauty and personal care items, and nutritional supplements. Established in 2001, the firm, initially known as Shop Apotheke Europe N.V., officially rebranded to Redcare Pharmacy N.V. in June 2023. Its operational headquarters are situated in Sevenum, the Netherlands.
0RJT Stock 12 Month Forecast
Average Price Target
€91.29
▲(31.82% Upside)